Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Dr. Brian Durie

Home/Tag:Dr. Brian Durie
22 11, 2013

ASH insight from Dr. Brian Durie

Tags: , , |7 Comments

IMF Medical Director, Dr. Brian Durie, has written a pair of posts about this year's ASH.  Here are the 8 new therapy agents that Dr. Durie will be watching: anti-CD 38 monoclonal antibodies (MAb) daratumumab (abstracts #227 and #1986) and SAR 650984 (#284)  MLN 9708 (ixazomib citrate: abstracts #535, 1944, and 1983) ARRY 520 (abstracts

21 10, 2013

New pathway may hold key to multiple myeloma cure

Tags: , , , , , |16 Comments

Could immunotherapy be the key to a multiple myeloma cure?  One thing's for sure; new drugs like elotuzumab and daratumumab offer hope that researchers are developing new and significant ways to attack our cancer. The International Myeloma Foundation's, Dr. Brian Durie, blogs about immunotherapy in this month's edition of the IMF's Myeloma Minute.  Here's an

18 10, 2013

More about chemo brain

Tags: , |3 Comments

Yesterday I ran a story about a chemo brain study that's recruiting participants at Moffitt Cancer Center in Tampa.  My good friend, Robin Tuohy, forwarded me a pair of additional links about chemo brain, including a study following stem cell transplantation, and a  YouTube video by Dr. Durie on the topic:  

12 09, 2013

Black Swan Research Initiative (Part Three)

Tags: , , |5 Comments

Let me preface today's post by admitting, I was a bit disappointed with the answers to our questions by the IMF's Dr. Brian Durie, the creative mind behind Black Swan. I'm afraid I overloaded him with so many specific questions that he felt compelled to keep his answers general and brief.  After all, Dr. Durie

11 09, 2013

Black Swan Research Initiative (Part Two)

Tags: , , , , , , , |19 Comments

With few exceptions, most myeloma specialists don't believe that our cancer can be cured using therapy options available today.  These exceptions include a small percentage (5-10%) of allogeneic (donor) transplant recipients, and possibly some low risk, Total Therapy grads from Arkansas.  Any others are considered outliers; rare exceptions that don't fit the norm. Five years

19 06, 2013

Myeloma Updates: Durie/Novis insight & support group shout-out

Tags: , , , , , |5 Comments

I have several different items to share with you today.  First, I have been saving a link to an in-depth article OncLive ran a week ago about the International Myeloma Foundation's power couple, Dr. Brian Durie and Susie Novis.  The article features fascinating personal insights, most of which were new to me; and I know

16 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Two)

Tags: , , , , , , , , , , , |7 Comments

Before I get started, did you happen to see the MMRF's Kathy Giusti interviewed in the trendy tech magazine, Fast Company?  Interesting approach.  Simply click-on the headline link below to access the interview: Using Data To Treat Cancer And Drive Innovation How a pair of savvy renegades are forcing collaboration in cancer R&D--and saving lives.

30 03, 2013

Black Swan Initiative: Let’s focus on the possibilities

Tags: , , , , , , |25 Comments

After re-reading the comments my blog post generated Thursday, I can already tell it's time to dial-things-back a bit.  I had a chance to speak with someone close to the new Black Swan Initiative roll-out today.  He preferred I not quote him or use his name; he didn't want to upstage the announcement or contribute

9 03, 2013

Wall Street Journal features article about new myeloma therapies

Tags: , , , , , , , |7 Comments

A good friend of mine, long-lived myeloma survivor Paula Van Riper, was recently featured in an excellent Wall Street Journal article about the recent FDA approvals of Kyprolis and Pomalyst.  The IMF's Medical Director, Dr. Brian Durie, is interviewed, along with Dr. David Siegel, chief of the myeloma division at John Theurer Cancer Center in

8 03, 2013

Ongoing diagnostics are used at different times and in different ways by different docs

Tags: , , , , , , , |8 Comments

I was running out of time and energy yesterday.  PET scan, Velcade infusion and other tests went fine and I arrived safely home by 4 PM.  There is a significant difference in the way doctors around the country test and monitor their patients--an alarming difference. Yesterday I wrote this: I have been writing about Total

9 01, 2013

Convincing evidence that drinking soda isn’t good for myeloma patients

Tags: , , , , , |8 Comments

Danny Parker has been forwarding me information about how bad drinking soda is for me ever since he saw me drinking a Diet Coke the last time we met.  So Danny, this expose' I just posted about the evils of soda pop on was written for you, good friend: More damning evidence against NutraSweet?

7 12, 2012

Importance of accurate diagnostics and how to treat patients that cannot transplant

Tags: , , , , |2 Comments

In-between Dr. San-Miguel's smoldering myeloma presentation and Dr. Durie's presentation about treating patients that aren't stem cell transplant candidates, an animated, emotional exchange took place among panel participants. Specifically, Dr. San-Miguel strenuously objected to using X-rays alone to warn of possible bone involvement in smoldering myeloma patients.  He made the same point that I reported

7 12, 2012

Controversies in Multiple Myeloma IMF Symposium today in Atlanta

Tags: , , , , , , , |2 Comments

The IMF's annual Satellite Symposium kicks-off ASH each year.  This year's event is at the Georgia World Congress Center in Atlanta.  Pretty impressive place!  And very impressive agenda. Titled "Controversies in Multiple Myeloma: Current Debates in Optimal Care, the five hour event features a who's who of the international myeloma world.  Check-out the faculty list: